Aytu Biopharma Inc expected to post a loss of 31  cents a share - Earnings Preview

Aytu Biopharma

14/05/2021 22:15

* Aytu Biopharma Inc  AYTU.OQ   AYTU.O  is expected to show a
rise in quarterly revenue when it reports results on May 17 .
* The Englewood, Colorado-based company is expected to report 
 a 72.4% increase in revenue to $14.065 million from $8.16
million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Aytu Biopharma Inc is
for a loss of 31 cents per share. For the same quarter last
year, the company reported a loss of $1.50 per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Aytu Biopharma
Inc is $19.25​, about 72.9% above​ its last closing price
of $5.22. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020  -0.38       -0.44      -0.70     Missed  -59.1
 Sep. 30 2020  -0.55       -0.55      -0.40     Beat    27.3
 Jun. 30 2020  -0.50       -0.35      -0.20     Beat    42.9​
 Mar. 31 2020  -1.91       -2.20      -1.50     Beat    31.8
 Dec.          -2.32​      -2.45      -0.10     Beat    95.9​
 31​ 2019​                                              
 Sep. 30 2019  -3.00       -2.75      -3.20     Missed  -16.4​
 Jun. 30 2019  -2.50       -3.30      -3.20     Beat    3
 Mar. 31 2019  -5.82       -5.80      -5.00     Beat    13.8
 This summary was machine generated May 14 at 21:15 GMT.  All
figures in US dollars unless otherwise stated